-+ 0.00%
-+ 0.00%
-+ 0.00%

Climb Bio Q4 2024 GAAP EPS $(0.13) Beats $(0.15) Estimate

Benzinga·03/25/2025 20:08:48
Listen to the news
Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.15) by 13.33 percent. This is unchanged from the same period last year.